Calibrating Parametric Subject-specific Risk Estimation by Cai, Tianxi et al.
Harvard University
Harvard University Biostatistics Working Paper Series
Year  Paper 
Calibrating Parametric Subject-specific Risk
Estimation
Tianxi Cai∗ Lu Tian† Hajime Uno‡
Scott D. Solomon∗∗ L. J. Wei††
∗Harvard University, tcai@hsph.harvard.edu
†Northwestern University, lutian@northwestern.edu
‡Dana Farber Cancer Institute, huno@hsph.harvard.edu
∗∗Brigham & Women’s Hospital
††Harvard University, wei@hsph.harvard.edu
This working paper is hosted by The Berkeley Electronic Press (bepress) and may not be commer-
cially reproduced without the permission of the copyright holder.
http://biostats.bepress.com/harvardbiostat/paper92
Copyright c©2008 by the authors.
CALIBRATING PARAMETRIC SUBJECT-SPECIFIC RISK ESTIMATION
T. Cai1, L. Tian2, Hajime Uno3, Scott D. Solomon4, and L.J. Wei1
1Department of Biostatistics, Harvard University, Boston, MA 02115, USA
2Department of Preventive Medicine, Northwestern University,Chicago, IL 60611, U.S.A
3Department of Biostatistics and Computational Biology, Dana Farber Cancer Institute, Boston,
Massachusetts 02115, U.S.A.
4Cardiovascular Division, Brigham & Women’s Hospital, Boston, Massachusetts 02115, U.S.A.
SUMMARY
For modern evidence-based medicine, decisions on disease prevention or management strategies
for individuals in a population are often guided by a risk index system. For each individual,
the system provides an estimate using the subject-specific “baseline” information for the risk of
experiencing a future disease-related clinical event. Such a risk scoring scheme is usually derived
from an overly simplified parametric model. To validate a model-based procedure, one may perform
a standard global evaluation via, for instance, the ROC analysis. In this paper, we propose a method
to calibrate the risk index system at a subject level. Specifically, a consistent estimation procedure
is derived for the t-year mortality rate of individuals who have the same estimated parametric risk
score. Furthermore, the corresponding pointwise and simultaneous confidence interval estimators
are also provided over a range of risk scores of interest. The proposals are illustrated with a data
set from a large clinical trial for evaluating various therapies for treating high risk patients after
myocardial infarction.
Keywords: Cardiovascular diseases; Cox’s model; Nonparametric functional estimation; Risk in-
dex; ROC analysis; Survival Analysis.
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1. INTRODUCTION
The choice of disease prevention or management strategy for an individual from a population of
interest is often made based on her/his risk of experiencing a certain clinical event during a specific
follow-up time period. Subjects classified as high risk may be recommended for intensive prevention
or therapy. The risk is usually estimated via a parametric or semi-parametric regression model
using ‘baseline” risk factors/markers. For example, recently Eagle et al. (2004) created a simple
bedside risk index system to predict 6-month post-discharge mortality for patients hospitalized due
to acute coronary syndrome (ACS). To estimate each individual risk, a Cox’s proportional hazards
model (Cox, 1972) was utilized to fit the data from the Global Registry of Acute Coronary Events
(GRACE) involving 17142 patients. The final model for prediction, consisting of nine covariates,
was developed using information on post-discharge follow-up mortality and all potential predictors
taken at admission as well as during hospitalization. The 6-month post-discharge mortality rate is
then estimated with the fitted model for each future individual patient.
An empirical model, such as a Cox model, is merely an approximation to the true model. It is
crucial to validate or evaluate the performance of a working model for appropriate clinical decision
making. In addition to checking the fitted model with routine goodness of fit techniques, the model-
based scoring system is often evaluated or validated globally based on specific summary measures, for
example, from the standard receiver operating characteristic curve (ROC) (Pepe et al., 2004; Wang
et al., 2006; Ware, 2006; Cook, 2007; Uno et al., 2007). For the aforementioned GRACE study, the
investigators used an independent cohort of 7638 patients to validate their system with an overall
c-statistic. However, even if the risk index system is acceptable using a global average measure,
for the group of patients with the same model-based risk score, the corresponding parametric risk
estimator may not estimate its true mortality rate well. Consequently clinicians may be misguided
in choosing inappropriate therapies for treating these individuals.
In this article, we propose a procedure for calibrating the parametric risk estimates. Specifically,
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under a general survival analysis setting, a consistent estimation procedure is proposed for the t-
year mortality rate of patients grouped by a parametric risk index system. Furthermore, we provide
pointwise and simultaneous confidence intervals for such risks over a range of estimated risk scores.
These interval estimates quantify the precision of our consistent point estimator. Moreover, the
upper or lower bounds of the intervals provide valuable information for the complex cost-benefit
decision making. Note that our proposal is also useful for calibrating a risk index system when
applied to populations different from the study population. For example, the Framingham Risk
Score (Anderson et al., 1991) for predicting the risk of Coronary Heart Disease (CHD) was developed
based on a US population. Its applicability to other populations has been extensively investigated
in recent years ( D’Agostino et al., 2001; Brindle et al., 2003; Zhang et al., 2005). For a new
population, our procedure can be used to assess the true risk of CHD for subjects with any given
Framingham Risk Score.
We illustrate the new proposal with a data set from the ”Valsartan in Acute Myocardial Infarc-
tion” (VALIANT) study (Pfeffer et al., 2003). This large clinical study was conducted to evaluate
the effect of angiotensin-converting-enzyme (ACE) inhibitors on overall mortality among patients
with myocardial infarction complicated by left ventricular systolic dysfunction and/or heart failure.
The trial was designed to compare three treatments, ARB valsartan, ACE inhibitor captopril and
a combination of these two drugs, for treating high risk patients after myocardial infarction with
respect to mortality and morbidity. The study was conducted from 1999 to 2003 with a total of
14703 patients randomly, equally assigned to the three groups. The median follow-up time is 24.7
months after randomization. At the end of the studies, 979, 958 and 941 patients died in the
three treatment groups, respectively. There are no significant differences among three groups with
respect to the overall mortality. On the other hand, the rich VALIANT data base provides valu-
able information about preventing future high risk patients from developing cardiovascular-related
diseases after MI with certain complications. In this paper, for simplicity, we used eleven baseline
3
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covariates from each study subject considered by Solomon et al. (2005) in our analysis. These
eleven predictors are potentially the most significant ones among the risk factors/markers identified
by Anavekar et al. (2004) for the overall mortality of VALIANT patients. We fitted the survival
data with an additive Cox model using these eleven covariates to obtain a parametric risk score
for each individual. We then estimated the t-year mortality rate consistently for subjects with a
given parametric score value to calibrate the model-based risk assessment. Lastly, we constructed
simultaneous and pointwise interval estimates for making inferences about such mortality rates over
a range of parametric risk scores.
2. CONSISTENT ESTIMATOR FOR MEAN RISK OF SUBJECTS WITH THE
SAME MODEL-BASED RISK SCORE
Consider a subject randomly drawn from the study population. Let T˜ be its time to a specific
event and U be the corresponding set of “baseline” risk factors/markers. Assume that T˜ has a
continuous distribution given U . Also, let P(U) = pr(T˜ < t0 | U), the risk of this individual
experiencing the event by a specific time point t0 conditional on U . The event time T˜ may be
censored by a random variable C which is assumed to be independent of T˜ and U . For T˜ , one can
only observe T = min(T˜ , C) and ∆ = I(T˜ ≤ C), where I(·) is the indicator function. Our data
{(Ti,∆i, Ui), i = 1, · · · , n} consist of n independent copies of (T,∆, U).
For a given U = u, P(u) may be consistently estimated nonparametrically. In practice, however,
such a nonparametric functional estimate does not behave well when the dimension of U is greater
than one. A standard, feasible way to reduce the dimension of u is to approximate P(u) with a
working parametric or semi-parametric model such as the Cox proportional hazards model:
P(u) = g{log Λ(t0) + β′x}, (2.1)
where g(s) = 1 − e−es , Λ(·) is the working baseline cumulative hazard function for T˜ , x, a p × 1
vector, is a function of u, and β is an unknown vector of regression parameters.
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To obtain an estimate for P(u) via (2.1), one may employ the maximum partial likelihood
estimator βˆ for β with all mortality information from the data collected during the study time
period [0, t0]. That is, βˆ is the maximizer of the log partial likelihood function,
n∑
i=1
∫ t0
0
[
β′Xi − log
{
n∑
j=1
Yj(t)e
β′Xj
}]
dNi(t), (2.2)
where Ni(t) = I(Ti ≤ t)∆i and Yi(t) = I(Ti ≥ t), for i = 1, · · · , n. When the model (2.1) is
correctly specified, βˆ consistently estimates the true value of β. In Appendix A, we show that under
a rather mild condition, βˆ converges to a finite constant β0, as n→∞, even when the model (2.1) is
misspecified. This large sample stabilization property is critical for establishing a risk score system.
Next, we estimate the function Λ(t) in (2.1) with the standard Breslow’s estimator (Kalbfleisch
& Prentice, 2002),
Λˆ(t) =
n∑
i=1
∫ t
0
dNi(s)∑n
j=1 Yj(s)e
βˆ′Xj
,
which is a step function that only jumps at observed failure time points. It follows that a model
based estimate of P(u) is Pˆ(u) = g(γˆ′~x), where γˆ = (log{Λˆ(t0)}, βˆ′)′ and ~x = (1, x′)′. Again,
in Appendix A, we show that under the working model (2.1), Pˆ(u) converges to a deterministic
function P¯(u) in probability, as n → ∞. When (2.1) is correctly specified, Pˆ(u) is consistent for
P(u).
Although most likely (2.1) is not the true model, the parametric risk scores {Pˆ(u)} or {γˆ′~x}
can be used as a risk index system for grouping future subjects in a population similar to the study
population. Now, consider a future subject whose (T˜ , U) = (T˜ 0, U0) and Pˆ(U0) = v. Then it is not
clear that v is a reasonable estimate for the risk of this individual experiencing the event before
time t0. Therefore, to calibrate the subject-level model-based risk estimate, one needs a consistent
estimate for
τ(v; t0) = pr(T˜
0 < t0 | Pˆ(U0) = v), (2.3)
the mortality rate among subjects with risk score Pˆ(U0) = v. Here, the probability is with respect
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to T 0, U0 and {(Ti, Ui,∆i), i = 1, · · · , n}.
To this end, let Λv(t) = − log{1 − τ(v; t)}, 0 ≤ t ≤ t0, the “cumulative hazard function” for
future subjects whose estimated risk index score is v. First, one may use a nonparametric kernel
Nelson-Aalen estimator smoothed over v for Λv(t) with the triplets {(Ti,∆i, Pˆ(Ui)), i = 1, ..., n}.
Specifically, as for the one-sample estimation of the cumulative hazard function in standard survival
analysis, we consider the class of potential estimators which are step functions over t and only jump
at the observed failure time points with jump sizes dΛv(t) = Λv(t)−Λv(t−). Then a nonparametric
functional estimator for dΛv(t) can be obtained by minimizing
n∑
i=1
Kh(Dˆvi)
{
dNi(t)− Yi(t)dΛv(t)
}2
, (2.4)
where dNi(t) = Ni(t) − Ni(t−), Dˆvi = ψ{Pˆ(Ui)} − ψ(v), K(·) is a smooth symmetric density
function, Kh(x) = K(x/h)/h, h is a bandwidth such that h → 0 and nh2 → ∞ as n → ∞,
and ψ(·) : (0, 1) → (−∞,∞) is a known increasing smooth transformation function (Wand et al.,
1991; Park et al., 1997). This local constant estimator essentially assumes that for v′ in a small
neighborhood of v, dΛv′(t) ≈ dΛv(t). The resulting minimizer of (2.4) is
dΛ˜v(t) =
∑n
i=1Kh(Dˆvi)dNi(t)∑n
i=1Kh(Dˆvi)Yi(t)
.
The corresponding estimator for Λv(t0) is
Λ˜v(t0) =
∫ t0
0
∑n
i=1Kh(Dˆvi)dNi(t)∑n
i=1Kh(Dˆvi)Yi(t)
. (2.5)
When Pˆ(Ui) is subject-specific, not a function of the data, the limiting distribution of such a
nonparametric estimator with a fixed v has been derived by Dabrowska (1989) and Du & Akritas
(2002). Here, we are interested in the behavior of the estimator (2.5) over a set of risk scores v at
a specific time point t0.
The above kernel estimator can potentially be improved by considering a local linear, not con-
stant, approximation to dΛv(t) around v (Fan & Gijbels, 1996; Li & Doss, 1995). That is, we
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replace dΛv(t) in (2.4) by a local linear function a + b{ψ(v′) − ψ(v)} with unknown intercept and
slope parameters a and b, where v′ is in a “neighborhood” of v. The resulting estimator dˆΛv(t) is
the intercept “a” of the vector (a, b)′ which minimizes
n∑
i=1
Kh(Dˆvi)
{
dNi(t)− Yi(t)(a+ Dˆvib)
}2
. (2.6)
The corresponding estimator Λˆv(t) for Λv(t) is the sum of dˆΛv(·) over all distinct observed death
times by t. The resulting estimator for τ(v; t0) is τˆ(v; t0) = 1− exp{−Λˆv(t0)}.
In Appendix B, we show that under mild regularity conditions, if h = O(n−ν) with 1/5 < ν <
1/2, τˆ(v; t0) is consistent for τ(v; t0), uniformly in v ∈ J = [ψ−1(ql+h), ψ−1(qr−h)], where (ql, qr)
is a subset contained in the support of ψ{P¯(U)}.
3. POINTWISE AND SIMULTANEOUS INTERVAL ESTIMATION
PROCEDURES FOR τ(v; t0) OVER RISK SCORE v
For any fixed v ∈ J , we show in Appendix B that for large n and h = O(n−ν) with 1/5 < ν <
1/2, the distribution of
(nh)
1
2
{
Λˆv(t0)− Λv(t0)
}
(3.1)
can be approximated well by the conditional distribution of a mean-zero normal
n−
1
2h
1
2
n∑
i=1
Kh(Dˆvi)Vˆi(v; t0)Vi + (nh) 12
{
Λˆv(t0, γˆ
∗)− Λˆv(t0)
}
, (3.2)
given the data, where {Vi, i = 1, · · · , n} are standard normal random variables generated indepen-
dent of the data,
Vˆi(v; t0) =
∫ t0
0
dNi(s)− Yi(s)dΛˆv(s)
n−1
∑n
j=1Kh(Dˆvj)Yj(s)
,
Λˆv(t0, γ) is given in (B·3) and γˆ∗ is given in (B·6). Here, Λˆv(t0, γˆ∗) is a random perturbed version of
the observed Λˆv(t0) with the same perturbation random sample {Vi, i = 1, · · · , n} which accounts
for the extra variability in γˆ. Although asymptotically one only needs the first term of (3.2) due to
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the fact that γˆ from the working Cox model is of order root-n, the inclusion of the second term is
likely to improve the approximation to the distribution of (3.1) in finite sample. This perturbation
method is similar to the so-called wild bootstrapping (Wu, 1986; Ha¨rdle, 1990; Mammen, 1992)
and has been utilized successfully for a number of interesting problems in survival analysis (Jin
et al., 2001; Park & Wei, 2003; Cai et al., 2005). Note that the distribution of (3.2) can be easily
approximated by generating a large number, say M , of realizations of {Vi, i = 1, · · · , n}.
With the above large sample approximation, for any v ∈ J , one may obtain a variance estimator
of (3.1), σˆ2v(t0), based on the empirical variance of M realizations from (3.2). For any given α ∈
(0, 1), a 100(1− α)% confidence interval for Λv(t0) can then be obtained as
Λˆv(t0)± (nh)−1/2cσˆv(t0),
where c is the 100(1 − α/2)th percentile of the standard normal. Subsequently, the corresponding
pointwise 100(1− α)% confidence interval for τ(v; t0), the mortality rate with score v, is
1− exp
{
−Λˆv(t0)± (nh)−1/2cσˆv(t0)
}
. (3.3)
To make inference about the mortality rate over a range of v, one may construct simultaneous
confidence intervals for {τ(v; t0), v ∈ J } by considering a sup-type statistic
W = supv∈J
∣∣∣∣∣(nh) 12 Λˆv(t0)− Λv(t0)σˆv(t0)
∣∣∣∣∣ . (3.4)
However, as a process in v, the distribution of (nh)
1
2{Λˆv(t0)−Λv(t0)} does not converge to a proper
distribution, as n → ∞. Therefore, we cannot use the standard large sample theory for stochastic
processes to obtain a finite sample approximation to the distribution of W. On the other hand, by
the strong approximation arguments and extreme value limit theorem (Bickel & Rosenblatt, 1973),
in Appendix B, we show that a standardized version of W converges in distribution to a proper
random variable. In practice, for large n, one can approximate the distribution ofW byW ∗, the sup
of the absolute value of (3.2) divided by σˆv(t0), with (3.2) perturbed by the same set of perturbation
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variables {Vi, i = 1, · · · , n} for all v ∈ J . It follows that the 100(1 − α)% simultaneous confidence
interval for τ(v; t0) is
1− exp
{
−Λˆv(t0)± (nh)−1/2d σˆv(t0)
}
, (3.5)
where the cutoff point d is chosen such that pr(W ∗ < d) ≥ 1− α.
As for any nonparametric functional estimation problem, the choice of the smoothing parameter
h for τˆ(v; t0) is crucial for making inferences about τ(v; t0). To incorporate censoring, we propose
to obtain an “optimal” h by minimizing mean integrated squared martingale residuals over time
interval (0, t0) through the standard K-fold cross validation procedure. Such a procedure has been
successfully used for bandwidth selection in Tian et al. (2005). Specifically, we randomly split the
data into K disjoint subsets of about equal sizes denoted by {Jk, k = 1, · · · , K}. For each k, we
use all observations which are not in Jk to obtain Λv(t) with a given h. Let the resulting estimators
be denoted by Λˆv(k)(t). We then use the observations from Ik to calculate the sum of integrated
squared martingale residuals∫ t0
0
∑
j∈Ik
{
Nj(t)−
∫ t
0
Yj(s)dΛˆvˆj(k)(s)
}2
d
{∑
j′∈Ik
Nj′(t)
}
, (3.6)
where vˆj = Pˆ(uj). Lastly we sum (3.6) over k = 1, · · · , K, and then choose h by minimizing this
sum of K martingale residuals. Since the order of such optimal bandwidth is expected to be n−1/5
(Fan & Gijbels, 1995), the bandwidth we use for estimation is the minimizer of (3.6) multiplied by
a factor n−d0 with 0 < d0 < 3/10 such that it is of order n−v with 1/5 < v < 1/2. This assures that
the resulting functional estimator Λˆv(t0) with the data-dependent smooth parameter has the above
desirable large sample properties.
4. EXAMPLE
We illustrate the new proposal with the data combined from three treatment groups of the
VALIANT study described in the introduction. Here, the vector U of potentially important base-
line risk factors/markers for overall mortality consists of age, Killip class (KC), eGFR, history of
9
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MI (MI), history of congestive heart failure (HF), percutaneous coronary intervention after index
MI (CorInt), atrial fibrillation after index MI (AF), history of diabetes (Dia), history of chronic
obstructive pulmonary disease (COPD), new left bundle-branch block (BBB), and history of angina
(Ang). There are n = 14088 patients (out of a total of 14703) in our analysis, who had complete in-
formation about these eleven covariates. The Kaplan-Meier estimate for overall survival for patients
in the analysis is given in Figure 1.
First, suppose that we are interested in predicting the 6-month mortality rates of future patients.
To this end, we let t0 = 6(month) and fitted the survival observations truncated slightly after 6
months with a Cox model (2.1) and x = u. The resulting vector of the regression coefficient estimates
βˆ is given in Table 1. These estimates, coupled with the intercept estimate for γˆ of −6.02, create a
risk score index Pˆ(u) for 6 month mortality of future patients.
Now, for a given Pˆ(u) = v, to obtain τˆ(v, 6), we let K(·) be the Epanechnikov kernel, and
ψ(v) = log{− log(1− v)} which leads to ψ{Pˆ(U)} = γˆ′ ~X. The smoothing parameter h = 0.18 was
obtained by multiplying a factor of 1/2, which is of order n−0.07, to the minimizer of the integrated
mean squared martingale residuals defined in (3.6) with 10-fold cross validation. Furthermore,
we chose the 2nd and 98th percentiles of the empirical distribution of {γˆ′ ~Xi, i = 1, · · · , n} as
the boundary points ql and qr for interval J . To approximate the distribution of (3.1) and W in
(3.5), we used the perturbation-resampling method (3.2) with 500 independent realized samples of
{Vi, i = 1, · · · , n} from the standard normal distribution.
In Figure 2(a), we present a smoothed density estimate for Pˆ(U), which provides useful infor-
mation regarding the relative size of the subgroup of individuals with Pˆ(U) = v, where v ∈ J =
[0.02, 0.24]. In Figure 2(b), we present the point estimates τˆ(v, 6) (solid curve) and 95% pointwise
(dark shaded) and simultaneous (gray shaded) interval estimates for τ(v, 6). The dashed line is 45
degree reference straight line.
Note that the estimated risk scores for most VALIANT patients are less than 0.15. For groups
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of subjects with low risk scores, their interval estimates tend to be tight. For example, for subjects
with Pˆ(u) = 0.05, the true 6-month mortality rate is likely to be between 0.03 and 0.05, based
on the 95% pointwise confidence interval. The corresponding simultaneous confidence interval is
[0.02, 0.06]. For patients whose risk scores are greater than 0.15, the interval estimates are relatively
wide as expected. For example, the true mortality rate for patients with Pˆ(u) = 0.20 is likely to
be from 0.19 to 0.25, the boundaries of the 95% pointwise confidence interval. The simultaneous
interval is [0.18, 0.27].
Next, suppose that we are interested in predicting long term survival for future patients similar
to the VALIANT study population. Here, we let t0 = 24 months and fitted the survival observations
slightly truncated at 24 months with a Cox model and x = u. The resulting regression coefficient
estimates are also given in Table 1. For this case, the bandwidth h = 0.15 and the range of
the estimated risk score v is from 0.04 to 0.48. The smoothed density function estimation of the
parametric score is given in Figure 1(c). Note that relatively few patients have scores beyond 0.3.
Our consistent point estimates (solid curve) for the true mortality rate and the 95% pointwise (dark
region) and simultaneous (gray region) intervals are given in Figure 1 (d). For example, for subjects
with a risk score of 0.1, our estimate for their 24 month mortality rate is 0.09 with 95% pointwise
and simultaneous confidence intervals being [0.08, 0.11] and [0.07, 0.12], respectively. For patients
whose risk scores are high, as expected, their interval estimates can be quite wide. For example, for
subjects with risk score of 0.3, the true mortality rate is likely to be between 0.26 and 0.37 based
on the 95% simultaneous confidence interval.
5. REMARKS
Due to the complexity of the disease process and the heterogeneity among subjects, it is unlikely
that a fitted parametric model would provide a good approximation to the true risk, P (T˜ < t0 | U),
for every subject in the population. The standard method to evaluate the adequacy of an assumed
11
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model is based on a utility or loss function of the observed and predicted responses averaged over the
entire study population. When the observed mortality rate is not small in a relatively large sample,
it is likely that a standard lack of fit test would reject the fitted model, which can be useful in
practice. In the present case, the univariate risk index system constructed from an empirical, semi-
parametric model can be quite useful for reducing the dimension of the baseline covariate vector
and grouping the subjects with “similar” risks. For a given risk scoring scheme, the new proposal
presented in this article can be utilized to make valid inferences about the true mortality rate for
subjects with the same model-based risk score. On the other hand, to evaluate whether the scoring
system effectively partitions the population, one needs to estimate the distribution of the risks for
these subjects. The index system works well if the distributions are tight around their centers over
a range of risk scores of interest. Further research on this challenging problem is warranted.
APPENDIX
In the appendix, we use the standard notations for the empirical process: Pn and P represent
the expectation with respect to the empirical distribution generated {(Ti,∆i, Xi), i = 1, · · · , n} and
the distribution generated by (T,∆, X), respectively. Similarly, Gn = n
1
2 (Pn − P). Throughout,
we assume that h = O(n−ν) with 1
5
< ν < 1
2
, K(x) is a symmetric smooth kernel function, has a
bounded support [-1, 1] and
∫
K˙(x)2dx <∞, where K˙(x) = dK(x)/dx. For convenience, we use the
following notations: Kj(x) = K(x)x
j, Kj,h(x) = Kj(x/h)/h and m2 =
∫ 1
−1K
2(x)dx. In addition,
we assume that the covariate vector X is bounded.
A Convergence of Pˆ(U)
First, we show that the in probability convergence of Pˆ(U) = g(γˆ′ ~X) → P¯(U) = g(γ′0 ~X) for any
given U , where γ0 = (log{Λ0(t)}, β′0)′, Λ0(t) =
∫ t
0
P{Y (s)λX(s)}/P{Y (s)eβ′0X}ds], β0 = argmaxβ L(β),
L(β) =
∫ t0
0
[
β′X − logP{Y (t)eβ′X}
]
P{Y (t)λX(t)}dt,
12
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and λx(t) is the hazard function of T˜ conditional on X = x. It suffices to show that βˆ → β0
and Λˆ0(t) → Λ0(t), in probability. Regardless of the adequacy of the the proportional hazards
model, L(β) is a convex function and Lˆ(β) → L(β) in probability, uniformly in β. Under the
condition that there is no vector ζ such that pr(T1 > T2 | ζ ′X1 > ζ ′X2, T2 ≤ t0) = 1, L(β) has a
unique maximizer β0. It follows from Theorem 2.1 of Newey & McFadden (1994) that β̂ → β0 in
probability. Furthermore, |βˆ − β0| = Op(n− 12 ). Furthermore, it follows from the same arguments in
Lin et al. (1993), |Λˆ0(t0)− Λ0(t0)| = Op(n− 12 ). This implies the consistency of Pˆ(U) for P¯(U).
B Asymptotic Properties of τˆ(v; t0)
We next derive the asymptotic properties of τˆ(v; t0), for v ∈ [ψ−1(ql + h), ψ−1(qr − h)]. Without
the loss of generality, we choose ψ(x) = log{− log(1 − x)}. Thus, ψ{P¯(U)} = γ′0 ~X, ψ{Pˆ(Ui)} =
γˆ′ ~Xi, and ψ{Pˆ(Ui)} − ψ{P¯(Ui)} = Op(n− 12 ). Let v˜ = ψ(v), λv(t) be the hazard function of T˜
conditional on γ′0 ~X = v˜, Λv(t) =
∫ t
0
λv(s)ds, ξ(·) be the density function of γ′0 ~X, and Mi(t) =
Ni(t) −
∫ t
0
Yi(s)dΛγ′0 ~Xi
(s). In view of τˆ(v; t0) = 1 − exp{−Λˆv(t)} and the delta method, in the
following we will establish the asymptotical properties of Λˆv(t). Furthermore, we will repeatedly
use the fact that
sup
e0∈[a,b]
∣∣∣∣ Pn [Kh(E − e0)F − P{Kh(E − e0)F}] ∣∣∣∣= Op [{(nh)−1 log(n)} 12] , (B·1)
where (Ei, Fi), i = 1, · · · , n are i.i.d realizations of the random vector (E,F ), satisfying that
supe0 P(|F |s | E = e0) <∞, ∀s > 0.
To derive the asymptotic properties of Λˆv(t0), we first show that asymptotically there is no extra
variation due to the uncertainty in γˆ. To this end, we write Λˆv(t0) = Λˆv(t0, γˆ) and aim to show
that for any γˆ = γ0 +Op(n
− 1
2 ),
sup
v
|Λˆv(t0, γˆ)− Λˆv(t0, γ0)| = op{(nh)− 12}, (B·2)
13
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where
Λˆv(t0, γ) =
∫ t0
0
pˆi
(2)
v (t, γ)dNˆ
(0)
v (t, γ)− pˆi(1)v (t, γ)dNˆ (1)v (t, γ)
pˆi
(2)
v (t, γ)pˆi
(0)
v (t, γ)− pˆi(1)v (t, γ)2
(B·3)
Nˆ (k)v (t, γ) = n
−1
n∑
i=1
Kh{Dvi(γ)}{h−1Dvi(γ)}kNi(t),
pˆi(k)v (t, γ) = n
−1
n∑
i=1
Kh{Dvi(γ)}{h−1Dvi(γ)}kYi(t),
and Dvi(γ) = ψ{g(γ′ ~Xi)}−ψ(v). Here and in the sequel, the sup is taken over [ψ−1(ql+h), ψ−1(qr−
h)] for v and over [0, t0] for t. To this end, we write
Λˆv(t0, γ) =
∫ t0
0
{
Rˆ(2)v (t, γ)dNˆ
(0)
v (t, γ)− Rˆ(1)v (t, γ)dNˆ (1)v (t, γ)
}
and seek to show that
sup
t,v
∣∣pˆi(k)v (t, γˆ)− pˆi(k)v (t, γt)∣∣ = op{(nh)− 12}. (B·4)
where
Rˆ(k)v (t, γ) =
pˆi
(k)
v (t, γ)
pˆi
(2)
v (t, γ)pˆi
(0)
v (t, γ)− pˆi(1)v (t, γ)2
, k = 1, 2.
Since pˆi
(k)
v (t, γ) =
∫
Kj,h(x− v˜)dPn{I(γˆ′ ~X ≤ x)Y (t)},
|pˆi(k)v (t, γˆ)− pˆi(k)v (t, γ0)| =
∣∣∣∣∫ Kj,h(x− v˜)dPn{I(γˆ′ ~X ≤ x)Y (t)− I(γ′0 ~X ≤ x)Y (t)}|∣∣∣∣
≤
∣∣∣∣n− 12 ∫ Kj,h(x− v˜)dGn{I(γˆ′ ~X ≤ x)Y (t)− I(γ′0 ~X ≤ x)Y (t)}|∣∣∣∣
+
∣∣∣∣∫ Kj,h(x− v˜)P{I(γˆ′ ~X ≤ x)Y (t)− I(γ′0 ~X ≤ x)Y (t)}|∣∣∣∣
≤h−1n− 12‖Gn‖Hδ +Op(n−
1
2 )
where Hδ = {[I(γ′ ~X ≤ x) − I(γ′0 ~X ≤ x)]Y (t) : x, s, |γ − γ0| ≤ δ} is a class of functions indexed
by x, s and δ. Furthermore, Hδ is uniformly bounded by an envelop function in the order of δ 12
with respect to L2 norm. By the maximum inequality (Theorem 2.14.2, Van der Vaart and Wellner,
1996) and the fact that |γˆ − γ0| = Op(n− 12 ), we have
h−1n−
1
2‖Gn‖Hδ . Op{h−1n−
1
2n−
1
4 log(n)}.
14
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It follows that |pˆi(k)v (t, γˆ) − pˆi(k)v (t, γ0)| = (nh)− 12 (nh2)− 14 log(n) + Op(n− 12 ) = op{(nh)− 12}. This,
together with (B·1), implies that
sup
t,v
|Rˆ(k)v (t, γ0)− Rˆ(k)v (t, γˆ)| = op{(nh)−
1
2}, k = 0, 1,
and sup
t,v
{|Rˆ(2)v (t, γ0)− r(2)v (t)|+ |Rˆ(1)v (t, γ0)|} = Op{(nh)−
1
2 log(n)
1
2 + h2},
where r
(2)
v (t) = 1/{ξ(v˜)Sv(t)} and Sv(t) = pr(T ≥ t|γ′0 ~X = v˜).
Next, we note that∣∣∣∣∫ t0
0
Rˆ(2)v (t, γˆ)dNˆ
(0)
v (t, γˆ)−
∫ t0
0
Rˆ(2)v (t, γ0)dNˆ
(0)
v (t, γ0)
∣∣∣∣ ≤ ²̂1 + ²̂2 + ²̂3
where
²̂1 = Pn
[∫ t0
0
∣∣∣Rˆ(2)v (t, γˆ)− Rˆ(2)v (t, γ0)∣∣∣Kh(γˆ′ ~X − v˜)dN(t)]+
²̂2 = Pn
∣∣∣∣{Kh(γˆ′ ~X − v˜)−Kh(γ′0 ~X − v˜)}∫ t0
0
∣∣∣Rˆ(2)v (t, γ0)− r(2)v (t)∣∣∣ dN(t)∣∣∣∣
²̂3 =
∣∣∣∣ Pn [{Kh(γˆ′ ~X − v˜)−Kh(γ′0 ~X − v˜)}∫ t0
0
r(2)v (t)dN(t)}
] ∣∣∣∣
We will bound these three terms in the following. For the first term,
²̂1 ≤ op{(nh)− 12}Pn
{
Kh(γˆ
′ ~X − v˜)N(t0)
}
= op{(nh)− 12}.
For the second term,
²̂2 ≤ h−1 sup
t
∣∣∣Rˆ(2)v (t, γ0)− r(2)v (t)∣∣∣ sup
x
[
Pn
{∣∣∣I(γˆ′ ~X ≤ x)− I(γ′0 ~X ≤ x)∣∣∣N(t0)}]
≤ Op{h−1(nh)− 12 log(n) 12 + h}Op(n− 12 ) = op{(nh)− 12}.
For the last term,
²̂3 ≤ n− 12h−1 sup
x
∣∣∣∣Gn [{I(γˆ′ ~X ≤ x)− I(γ′0 ~X ≤ x)}∫ t0
0
r(2)v (t)dN(t)
]∣∣∣∣+Op(n− 12 )
= Op{n− 12h−1n− 14 log(n)} = op{(nh)− 12}.
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Therefore,
sup
v
∣∣∣∣∫ t0
0
Rˆ(2)v (t, γˆ)dNˆ
(0)
v (t, γˆ)−
∫ t0
0
Rˆ(2)v (t, γ0)dNˆ
(0)
v (t, γ0)
∣∣∣∣ = op{(nh)− 12}.
Similarly, ∫ t0
0
Rˆ(1)v (t, γˆ)dNˆ
(1)
v (t, γˆ)−
∫ t0
0
Rˆ(1)v (t, γt)dNˆ
(1)
v (t, γ) = op{(nh)−
1
2},
and thus (B·2) holds. On the other hand, the arguments given in Li & Doss (1995) can be used
to show that supv |Λˆv(t0, γ0) − Λv(t0)| → 0, in probability. It follows that supv |Λˆv(t0) − Λv(t0)| ≤
supv |Λˆv(t0, γˆ)−Λˆv(t0, γ0)|+supv |Λˆv(t0, γ0)−Λv(t0)| → 0, in probability. This concludes the uniform
consistency of Λˆv(t0).
We next derive the asymptotic distribution of Ŵv(t0) = (nh) 12{Λˆv(t0)−Λv(t0)}. From (B·2), we
have Ŵv(t0) = W˜v(t0)+op(1), where W˜v(t0) = (nh) 12{Λˆv(t0, γ0)−Λv(t0)}. Noting that n 12h 52 = op(1)
and the decomposition that
W˜v(t0) = (nh) 12Pn
[∫ t0
0
{
Rˆ(2)v (t, γ0)Kh(γ
′
0
~X − v˜)− Rˆ(1)v (t, γ0)K1,h(γ′0 ~X − v˜)
}
dM(t)
]
+ (nh)
1
2
{
h2 + op(h
2)
2
∫ t0
0
pˆi
(2)
v (t, γ0)
2 − pˆi(1)v (t, γ0)pˆi(3)v (t, γ0)
pˆi
(2)
v (t, γ0)pˆi
(0)
v (t, γ0)− pˆi(1)v (t, γ0)2
∂2λv(t)
∂v˜2
ds
}
,
we have
W˜v(t0) = (nh) 12Pn
[∫ t0
0
{
Rˆ(2)v (t, γ0)Kh(γ
′
0
~X − v˜)− Rˆ(1)v (t, γ0)K1,h(γ′0 ~X − v˜)
}
dM(t)
]
+ op(1).
By integration by part and maximum inequality for empirical process, we have
(nh)
1
2Pn
{
K1,h(γ
′
0
~X − v˜)
∫ t0
0
Rˆ(1)v (t, γ0)Y (t)dM(t)
}
= op(1)
and
(nh)
1
2Pn
[
Kh(γ
′
0
~X − v˜)
∫ t0
0
{
Rˆ(2)v (t, γ0)− r(2)v (t)
}
dM(t)
]
= op(1),
uniformly in v˜. Therefore,
Ŵv(t) =(nh) 12Pn
{
Kh(γ
′
0
~X − v˜)
∫ t0
0
r(2)v (t)dM(t)
}
+ op(1). (B·5)
16
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For any fixed v (or v˜), by martingale central limit theorem,
(nh)
1
2Pn
{
Kh(γ
′
0
~X − v˜)
∫ t0
0
r(2)v (t)dM(t)
}
→ N{0, σ2v(t0)},
in distribution, as n→∞, where
σ2v(t0) = m2
∫ t0
0
r(2)v (t)dΛv(t).
It follows that for any fixed v, Ŵv(t) converges in distribution to N{0, σ2v(t0)}.
To demonstrate the validity of the resampling variance estimator, we define
γˆ∗ = (log{Λˆ∗0(t0)}, βˆ∗′)′, (B·6)
where
βˆ∗ = βˆ + Aˆ−1
n∑
i=1
∫ [
Vi
{
Xi − Πˆ
(1)(t,βˆ)
Πˆ(0)(t,βˆ)
}
− n
−1Pn
j=1 VjYj(t)e
βˆ′Xj{Πˆ(0)(t,βˆ)Xj−Πˆ(1)(t,βˆ)}
Πˆ(0)(t,βˆ)2
]
dNi(t)
log{Λˆ∗0(t0)} = log{Λˆ0(t0)}+
n−1
Λˆ0(t)
n∑
i=1
∫ t
0
[
Vi
Πˆ(0)(s,βˆ)
− n
−1Pn
j=1 VjYj(s)e
βˆ′Xj+Πˆ(1)(t,βˆ)′(βˆ∗−βˆ)
Πˆ(0)(s,βˆ)2
]
dNi(s)
Πˆ(k)(t, β) = n−1
∑n
j=1 Yj(t)e
β′XjX⊗kj and for any vector x, x
⊗0 = 1, x⊗1 = x and x⊗2 = xx′. It
is straightforward to show that the distribution of n
1
2 (γˆ∗ − γˆ) conditional on the data and the
unconditional distribution of n
1
2 (γˆ − γ0) converge to the same limiting normal distribution. Now
since γˆ∗ = γ0 +Op(n−
1
2 ), by (B·2),
(3.2) = n−
1
2h
1
2
n∑
i=1
Kh(Dˆvi)Vˆi(v; t0)Vi + op(1),
Thus the variance estimator for (nh)
1
2{Λˆv(t0)− Λv(t0)} is
σˆ2v(t0) =var
[
n−
1
2h
1
2
n∑
i=1
Kh(Dˆvi)Vˆi(v; t0)Vi
∣∣∣∣ (Ti,∆i, Ui), i = 1, · · · , n
]
+ op(1)
= Pn
hK2h (γˆ′ ~X − v˜)
{∫ t0
0
dN(t)− Y (t)dΛˆv(t)
pˆi
(0)
v (t, γˆ)
}2+ op(1)
= Pn
[
hK2h
(
γ′0 ~X − v˜
){∫ t0
0
r(2)v (t)dM(t)
}2]
+ op(1)
= P
{
hK2h
(
γ′0 ~X − v˜
)∫ t0
0
r(2)v (t)
2Y (t)dΛv(t)
}
+ op(1) = σ
2
v(t0) + op(1),
17
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which converges to σ2v(t0) in probability.
C Justification for the Validity of the Confidence Band for τˆ(v; t0)
We first justify that after proper standardization, the supermum type statistics
W = sup
v
∣∣∣∣∣(nh)
1
2 Λˆv(t0)− Λv(t0)
σˆv(t0)
∣∣∣∣∣
converges weakly. It follows from (B·5) and the consistency of σˆv(t0) for σv(t0) that
W = sup
v
∣∣∣∣ (nh) 12Pn
{
Kh(γ
′
0
~X − v˜)
∫ t0
0
r
(2)
v (t)
σv(t0)
dMi(t)
} ∣∣∣∣ +op(1).
This, together with the continuity of r
(2)
v (t)/σv(t0), implies that
W = sup
v
∣∣∣∣ (nh) 12Pn {Kh(γ′0 ~X − v˜)η} ∣∣∣∣ +op(1).
where
η =
∫ t0
0
r
(2)
ψ−1(γ′0 ~X)
(t)dM(t)
σψ−1(γ′0 ~X)
(t0)
If follows from the similar argument in Bickel & Rosenblatt (1973) that
pr {an(W − dn) < x} → e−2e−x
where
an =
{
2 log
(
ψ(qr)− ψ(ql)
h
)} 1
2
and dn = an + a
−1
n log
{
1
4m2pi
∫
K˙(t)2dt
}
.
Now, to justify the validity of the resampling procedure for constructing the confidence band, we
consider the statistics
W ∗ = sup
v
∣∣∣∣ (nh) 12σˆv(t0)
n∑
i=1
Vi
∫ t0
0
Kh(γˆ
′ ~Xi−v˜){dNi(t)−Yi(t)dΛˆv(t)}
pˆi
(0)
v (t,γˆ)
+ (nh)
1
2
{
Λˆv(t0, γˆ
∗)− Λˆv(t0, γˆ)
} ∣∣∣∣,
Again, since |γˆ∗ − γˆ| = Op(n− 12 ), from (B·2), we have
W ∗ = sup
v
∣∣∣∣ (nh) 12σˆv(t0)
n∑
i=1
Vi
∫ t0
0
Kh(γˆ
′ ~Xi−v˜){dNi(t)−Yi(t)dΛˆv(t)}
pˆi
(0)
v (t,γˆ)
∣∣∣∣ +op(1).
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It follows from the same argument as given in Tian et al. (2005) that,
sup
x
∣∣∣pr {an(W ∗ − dn) < x | (Ti,∆i, Ui), i = 1, · · · , n} − e−2e−x∣∣∣
→ 0, in probability as n→∞. Therefore, the conditional distribution of an(W ∗ − dn) can be used
to approximate the distribution of an(W − dn) for large n.
19
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Figure 1: The Kaplan-Meier Curve with the survival time data for the entire VALIANT study.
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Table 1: Estimates (Est) of the regression coefficients, the corresponding standard errors (SE) and
p-values by fitting the Cox model to the VALIANT data based on survival time information up to
t0.
Covariates
Age KC eGFR MI HF CorInt AF Dia COPD BBB Ang
Est .028 .289 -.012 .206 .242 -.433 .252 .241 .161 .220 .164
t0 = 6 SE .003 .032 .002 .066 .072 .107 .072 .061 .088 .108 .062
p-value .000 .000 .000 .002 .001 .000 .001 .000 .070 .042 .008
Est .030 .237 -.010 .295 .327 -.463 .296 .268 .243 .231 .235
t0 = 24 SE .002 .023 .001 .047 .051 .077 .052 .044 .062 .080 .045
p-value .000 .000 .000 .000 .000 .000 .000 .000 .000 .004 .000
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Figure 2: Prediction of 6-month and 24-month mortality risks based on the eleven risk factors.
The top panel shows the estimated density function of the model based risk estimate for (a) t0 = 6
months; and (c) t0 = 24 months. The lower panel shows the point (thick solid curve) estimate of the
true risk function τ(v, t0) along with their pointwise (dark shaded region) and simultaneous (light
shaded region) confidence intervals for (b) t0 = 6 months; and (d) t0 = 24 months. The dashed line
is the 45 degree reference line.
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(c) Estimated Density for 24 month mortality risk
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(b) Consistent estimate for τ(v, 6)
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(d) Consistent estimate for τ(v, 24)
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